Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis-Reference-Cited by-同舟云学术

Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis

Published:2017-12-19 Issue:5 Volume:124 Page:925-933
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Harshman Lauren C.¹^ORCID,Xie Wanling²,Moreira Raphael B.¹³,Bossé Dominick¹,Ruiz Ares Gustavo J.¹⁴,Sweeney Christopher J.¹,Choueiri Toni K.¹^ORCID

Affiliation:

1. Lank Center for Genitourinary Oncology; Dana-Farber Cancer Institute, Harvard Medical School; Boston Massachusetts

2. Department of Biostatistics and Computational Biology; Dana-Farber Cancer Institute; Boston Massachusetts

3. Oncoclinic Group, Alemao Oswaldo Cruz Hospital; Sao Paulo Brazil

4. Department of Clinical Oncology; University Hospital 12 de Octubre; Madrid Spain

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference38 articles.

1. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system;Lam;J Urol,2005

2. Systemic therapy for metastatic renal-cell carcinoma;Choueiri;N Engl J Med,2017

3. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial;Haas;Lancet,2016

4. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy;Ravaud;N Engl J Med,2016

5. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT) [abstract];Motzer;J Clin Oncol.,2017

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification and validation of a novel signature based on macrophage marker genes for predicting prognosis and drug response in kidney renal clear cell carcinoma by integrated analysis of single cell and bulk RNA sequencing;Aging;2024-03-20

2. Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival;Cancers;2024-01-28

3. Perioperative systemic therapy in renal cell carcinoma;Current Opinion in Supportive & Palliative Care;2023-10-06

4. Meta-analysis of perioperative immunotherapy in renal cell carcinoma: Available, but the jury is still out;Urologic Oncology: Seminars and Original Investigations;2023-09

5. Surrogacy of Recurrence-free Survival for Overall Survival as an Endpoint of Clinical Trials of Perioperative Adjuvant Therapy in Hepatobiliary-pancreatic Cancers;Annals of Surgery;2023-08-28